Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,338

Document Document Title
WO/2019/170705A1
This invention relates to a compound according to general formula (IA), which acts as a selective cysteine protease inhibitor; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination p...  
WO/2019/154769A1
The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.  
WO/2019/150323A1
Ionic liquids of creatine comprising a creatine anion and a cation., as well as their means of manufacture. Examples of the ionic liquids of creatine are choline creatinate, betaine ethyl ester creatinate and agmatine creatinate are desc...  
WO/2019/100261A1
A metformin hydrochloride synthesis system and a preparation method therefor, the synthesis system comprising a reaction apparatus (20), the reaction apparatus (20) being provided with a feed opening and a reactant discharge opening, and...  
WO/2019/088270A1
The present invention provides a compound that is highly safe and that is useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical compos...  
WO/2019/084451A1
Food compositions or dietary supplements comprising an effective amount of an additive that comprises at least one oral hypoglycemic agent for the treatment, prevention, control and management of blood sugar and insulin spikes associated...  
WO/2019/079707A1
The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods...  
WO/2019/071353A1
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...  
WO/2019/062661A1
The present invention relates to the field of pharmaceutical chemistry, and specifically, to a kind of oseltamivir derivatives that are neuraminidase inhibitors containing carbamido, a preparation method therefor, and medical uses thereo...  
WO/2019/055280A1
The invention provides diethanolamine and morpholine salts of ursolic acid. Compositions containing the salts, and methods of using the salts are also provided.  
WO/2019/047866A1
Disclosed are novel compounds, pharmaceutical compositions and methods of preparation and use thereof for treating disease affecting the central nervous system such as multiple sclerosis.  
WO/2019/008027A1
The present disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 means a fluorine atom or a perhalogeno linear alkyl radical containing 1, 2 or 3 carbon atoms; R2 means a chlorine atom, ...  
WO/2018/233326A1
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...  
WO/2018/226368A1
A method for removing carbon dioxide from a gaseous source, the method comprising: (i) contacting said gaseous source with an aqueous solution of a carbon dioxide sorbent that reacts with carbon dioxide to form an aqueous-soluble carbona...  
WO/2018/216926A1
Provided is a composition containing an alkyl lactate, an anti-hydrolysis agent, and water, wherein the anti-hydrolysis agent is a basic amino acid.  
WO/2018/210633A1
The present invention relates to a method for the production of phenylguanidines or the salts thereof by reacting an aniline that has electronegative substituents with a cyanamide-containing mixture.  
WO/2018/208647A1
Provided are embodiments of creatine and creatine ethyl ester (CEE) salts where the anion is an artificial (non-saccharide) taste-modifier. These compounds represent stable white non-hygroscopic solids or semisolids that can readily diss...  
WO/2018/172168A1
The present invention relates to a guanidine of the formula (I) and to the use thereof as catalyst for the crosslinking of a functional compound, especially a polymer having silane groups. The guanidine of the formula (I) described is pr...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/159650A1
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...  
WO/2018/135977A1
The invention relates to the field of pharmaceutical chemistry, namely to new biologically active substances and their use and to a method of production. In particular, the invention relates to a derivative of creatine - phenylcreatine, ...  
WO/2018/132827A1
Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolyt...  
WO/2018/106938A1
The present disclosure is directed to polymeric coatings. The coatings can include a substrate-coordinating functionality as well as additional functionality for interacting with the surrounding environment. For example, the coatings can...  
WO/2018/106907A1
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene...  
WO/2018/097172A1
The present invention provides: compounds represented by formula (IV) (in the formula, Ar represents a substituted or unsubstituted phenylene group; X and Z each independently represent a substituted or unsubstituted alkylene group, etc....  
WO/2018/096504A1
Compounds of Formula (I), including stereoisomers and salts thereof, and compositions, methods of treatment and prevention, and methods of preparing, the same: Formula (I) wherein X is O or a direct bond; wherein when X is O, R1 and R2 a...  
WO/2018/097126A1
Compounds represented by formula (I) or salts thereof. A fungicide or plant disease control agent containing as an active ingredient at least one selected from the group consisting of said compounds and salts thereof. In formula (I), Ar ...  
WO/2018/087753A1
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their int...  
WO/2018/081869A1
The present application relates to compounds of Formula (I) and salts thereof. The compounds of Formula (I) have antibacterial and anti-biofilm activities. The present application also relates to compositions comprising the compounds of ...  
WO/2018/060373A1
The present invention relates to drugs derived from elafibranor. It relates more specifically to a composition comprising at least one active ingredient, characterised in that at least one active ingredient comprises an elafibranor metfo...  
WO/2018/060962A2
The present invention relates to metformin amino acid compounds (SLNs), pharmaceutical compositions thereof, and methods of using them for the treatment of hyperglycemia, diabetes, and Type 2 diabetes. The compounds can be synthesized us...  
WO/2018/060959A1
The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases o...  
WO/2018/053643A1
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...  
WO/2018/035408A1
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Ch...  
WO/2018/029618A1
An antibacterial compound of formula I, wherein X is selected from fluoro or bromo, effective against Gram negative and Gram positive bacteria, and in particular against non-fermenting multiresistant bacteria affecting patients suffering...  
WO/2018/014111A1
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours po...  
WO/2017/205828A1
This invention relates to using a guanidinium-based ionic liquid as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the absorbent is...  
WO/2017/205807A1
This invention relates to using a eutectic mixture of two ionic liquids, as an absorbent material in an absorption chiller. The invention provides an absorption chiller comprising a mixture of a refrigerant and an absorbent, and the abso...  
WO/2017/197510A1
A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly ...  
WO/2017/195086A1
The present invention provides novel metformin salts, method of preparing, and pharmaceutical compositions containing the same. The metformin sesquihydrochloride and metformin dihydrochloride according to the present invention has improv...  
WO/2017/176246A1
Compositions and methods for cleansing the eyelid and treating an ocular condition are disclosed herein. A method for treating an ocular condition involves cleansing an eyelid with a first ophthalmic composition, wherein the first ophtha...  
WO/2017/164813A1
D The present invention relates to ion pair catalysts (I) comprising the cationic bisguanidinium ligand (A) and diperoxomolybdate anion (B). The present invention also relates to ion pair catalysts (III) comprising the cationic bisguanid...  
WO/2017/158379A1
The present invention provides a crystalline salt of chlorhexidine chloride having a spherical morphology under Scanning Electron Microscopy (SEM) comprising a chloride anion and a cation selected from the group consisting of calcium, so...  
WO/2017/070482A3
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.  
WO/2017/118582A1
The invention relates to an aqueous plating bath composition for electroless deposition of nickel or a nickel alloy, the composition comprising: (i) a source of nickel ions, wherein the aqueous plating bath composition further comprises ...  
WO/2017/119562A1
The present invention relates to an antithrombotic, antiplatelet and anticoagulant pharmaceutical composition containing, as an active ingredient, a compound isolated from Scolopendra subspinipes. More specifically, the compound of the p...  
WO/2017/114224A1
The present invention discloses a creatine mother liquor separation and purification processing system, wherein the system includes a mother liquor tank for containing the mother liquor following creatine synthesis, the mother liquor tan...  
WO/2017/114226A1
Disclosed in the present invention is a method for separating and purifying a creatine mother liquor: by means of a liquor delivery tube, pumping a mother liquor after creatine synthesis to be separated in an electrodialyzer, wherein the...  
WO/2017/106312A1
Embodiments described herein provide methods of treating various diseases or disorders using Sigma1 modulating compounds alone or in combination with other therapeutic agents.  
WO/2017/065495A3
The present invention relates to a compound for inhibiting the secretion of thymic stromal lymphopoietin (TSLP) from mast cells, and a use thereof. It has been confirmed that the compound of the present invention significantly inhibits t...  

Matches 1 - 50 out of 3,338